» Articles » PMID: 32973757

Basophil Activation As Marker of Clinically Relevant Allergy and Therapy Outcome

Overview
Journal Front Immunol
Date 2020 Sep 25
PMID 32973757
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

For some years now the basophil activation test (BAT) using flow cytometry has emerged as a powerful tool and sensitive marker that can be used to detect clinically relevant allergies, provide information on the severity of an allergic reaction, and monitor therapies. Compared to other diagnostic tests, BAT seems to have a better informative value in terms of clinical relevance. In general, the BAT can be used for the diagnosis of the most common forms of IgE-mediated allergy such as hymenoptera venom allergy, inhalant allergy, food allergy, and drug allergy. Various basophil markers and parameters have been established which, depending on the trigger of the respective allergy, can provide information on the clinical relevance of sensitization, on the development of natural tolerance, on trigger thresholds, and on the severity of the allergic reaction. The BAT also serves as a suitable follow-up instrument for various therapeutic approaches such as specific immunotherapy, desensitization protocols, or use of anti-IgE-antibodies for the various diseases. Quality controls for routine use, standardization, and automatization are expected to expand the range of applications for the above-mentioned indications.

Citing Articles

Biomarkers for the Molecular Diagnosis of IgE-Mediated Hymenoptera Venom Allergy in Clinical Practice.

Popescu F, Preda M, Antolin-Amerigo D, Rodriguez-Otero N, Ramirez-Mateo E, Smolinska S Int J Mol Sci. 2025; 26(1.

PMID: 39796126 PMC: 11719524. DOI: 10.3390/ijms26010270.


Applications of basophil activation test in paediatric allergic diseases.

Giulia D, Paola D, Armando D, Pasquale S, Domenico D, Francesca D World Allergy Organ J. 2024; 17(12):100998.

PMID: 39734398 PMC: 11681913. DOI: 10.1016/j.waojou.2024.100998.


Comparative Assessment of the Allergenicity of Hyaluronidases from (Pol d 2), (Ves v 2), and Venom (Api m 2).

Grosch J, Eberlein B, Waldherr S, Pascal M, Dorn B, San Bartolome C Toxins (Basel). 2024; 16(11).

PMID: 39591253 PMC: 11598713. DOI: 10.3390/toxins16110498.


Assessment of Hypersensitivity to House Dust Mites in Selected Skin Diseases Using the Basophil Activation Test: A Preliminary Study.

Krupka Olek M, Bozek A, Foks Ciekalska A, Grzanka A, Kawczyk-Krupka A Medicina (Kaunas). 2024; 60(10).

PMID: 39459395 PMC: 11509700. DOI: 10.3390/medicina60101608.


Basophil activation test in Hymenoptera venom allergy.

Eberlein B, Brockow K, Darsow U, Biedermann T, Blank S Allergol Select. 2024; 8:293-298.

PMID: 39211355 PMC: 11361271. DOI: 10.5414/ALX02522E.


References
1.
Mehlich J, Fischer J, Hilger C, Swiontek K, Morisset M, Codreanu-Morel F . The basophil activation test differentiates between patients with alpha-gal syndrome and asymptomatic alpha-gal sensitization. J Allergy Clin Immunol. 2018; 143(1):182-189. DOI: 10.1016/j.jaci.2018.06.049. View

2.
Kim S, Kim S, Chung S, Kim J, Lee S, Kim B . Changes in basophil activation during immunotherapy with house dust mite and mugwort in patients with allergic rhinitis. Asia Pac Allergy. 2018; 8(1):e6. PMC: 5796966. DOI: 10.5415/apallergy.2018.8.e6. View

3.
Santos A, Du Toit G, Douiri A, Radulovic S, Stephens A, Turcanu V . Distinct parameters of the basophil activation test reflect the severity and threshold of allergic reactions to peanut. J Allergy Clin Immunol. 2015; 135(1):179-86. PMC: 4282725. DOI: 10.1016/j.jaci.2014.09.001. View

4.
Brandstrom J, Vetander M, Sundqvist A, Lilja G, Johansson S, Melen E . Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy. 2019; 49(10):1328-1341. DOI: 10.1111/cea.13469. View

5.
Eberlein B, Krischan L, Darsow U, Ollert M, Ring J . Double positivity to bee and wasp venom: improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants. J Allergy Clin Immunol. 2012; 130(1):155-61. DOI: 10.1016/j.jaci.2012.02.008. View